## CHEERS checklist— note that the identification of locations within the paper refers to the revised version of the paper with tracked changes.

	Item		Reported on page no/ para
Section/item	No	Recommendation	no
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	Page 1, line 2
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	page 2
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	page 4
		Present the study question and its relevance for health policy or practice decisions.	Page 5 (end) and page 6 (first two paras)
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Page 7 (para 2)
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Page 4 (last para) and box on page 4-5.
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Page 6, paras 2-3
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Page 4 (last para) and box on page 4-5
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Page 7 para 1: three years before and four years after the start of the programme.
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Not applicable
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Page 6 (last para)
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	Page 7 and first two paras on page 8. Note that clinical effectiveness was not part of this study.
	11b	Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	Not applicable
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	Not applicable
Estimating resources and costs	13a	Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	Page 8 para 2
	13b	Model-based economic evaluation: Describe	Not applicable

		approaches and data sources used to estimate	
		resource use associated with model health states.	
		Describe primary or secondary research methods for	
		valuing each resource item in terms of its unit cost.	
		Describe any adjustments made to approximate to	
		opportunity costs.	
Currency, price date, and	14	Report the dates of the estimated resource quantities	Page 8, para 2.
conversion		and unit costs. Describe methods for adjusting	Appendix A13
2011/2131011		estimated unit costs to the year of reported costs if	/tpperial//tis
		necessary. Describe methods for converting costs into	
		a common currency base and the exchange rate.	
Choice of model	15	Describe and give reasons for the specific type of	Not applicable
		decision-analytical model used. Providing a figure to	
		show model structure is strongly recommended.	
Assumptions	16	Describe all structural or other assumptions	Not applicable
7.55411170115	10	underpinning the decision-analytical model.	Not applicable
Analytical methods	17	Describe all analytical methods supporting the	Page 7 paras 1-3 and page 8
, clour methods		evaluation. This could include methods for dealing	paras 1-2
		with skewed, missing, or censored data; extrapolation	para3 1-2
		methods; methods for pooling data; approaches to	
		validate or make adjustments (such as half cycle	
		corrections) to a model; and methods for handling	
		population heterogeneity and uncertainty.	
Results		population neterogeneity and uncertainty.	
Study parameters	18	Report the values, ranges, references, and, if used,	Not reported
Study parameters	10	probability distributions for all parameters. Report	Not reported
		reasons or sources for distributions used to represent	
		·	
		uncertainty where appropriate. Providing a table to	
Incremental costs and	19	show the input values is strongly recommended.  For each intervention, report mean values for the	Dago 12 12 table 1 page 14
	19	•	Page 12-13 table 1, page 14 tables 2-3,
outcomes		main categories of estimated costs and outcomes of interest, as well as mean differences between the	Appendix table A4
		,	Appendix table A4
		comparator groups. If applicable, report incremental cost-effectiveness ratios.	
Characterising uncertainty	20a	Single study-based economic evaluation: Describe the	Discussion of potential effects
		effects of sampling uncertainty for the estimated	of imprecise matching of
		incremental cost and incremental effectiveness	controls on page 15 (last
		parameters, together with the impact of	para) and page 16 (paras 1-2)
		methodological assumptions (such as discount rate,	para, and page 10 (paras 1 2)
		study perspective).	
	20b	Model-based economic evaluation: Describe the	Not applicable
	200	effects on the results of uncertainty for all input	Not applicable
		parameters, and uncertainty related to the structure	
		of the model and assumptions.	
Characterising	21	If applicable, report differences in costs, outcomes, or	Not reported
Characterising heterogeneity	21	cost-effectiveness that can be explained by variations	Not reported
Heterogeneity			
		between subgroups of patients with different baseline	
		characteristics or other observed variability in effects that are not reducible by more information.	
Discussion		that are not reducible by more imormation.	
Study findings, limitations,	22	Summarise key study findings and describe how they	Page 15 paras 3-4 and page
generalisability, and		support the conclusions reached. Discuss limitations	16 paras 1-5.
current knowledge		and the generalisability of the findings and how the	10 paras 1 3.
carrett knowledge		findings fit with current knowledge.	
Page Other			
Source of funding	23	Describe how the study was funded and the role of	Page 18 last para
		•	<del>-</del>

		the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Page 18 para 6

For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist